Amarin (AMRN) Dips Following FDA Orange Book Update
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corp Plc (NASDAQ: AMRN) shares are pressured following an update to the FDA's Orange Book.
The Book had Amarin's Vascepa with "no unexpired exclusivity for this product," though no NCE decision was made.
Shares are down 7.5 percent Friday afternoon.
The Book had Amarin's Vascepa with "no unexpired exclusivity for this product," though no NCE decision was made.
Shares are down 7.5 percent Friday afternoon.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
